<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00913250</url>
  </required_header>
  <id_info>
    <org_study_id>C-869</org_study_id>
    <nct_id>NCT00913250</nct_id>
  </id_info>
  <brief_title>A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Single-Blind, Crossover Study in Healthy Volunteers to Demonstrate the Bioequivalence of AVONEX® (Interferon Beta-1a) Solutions for Injection Produced by a Serum-Containing Manufacturing Process and by a Serum-Free Manufacturing Process</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Demonstrate the bioequivalence of a serum-free solution to a serum containing solution of
      Avonex.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">October 2003</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To demonstrate the bioequivalence of a serum-free Avonex and a serum-containing AVONEX® when given intramuscularly (IM) to healthy volunteers.</measure>
    <time_frame>Study duration is 72 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Serum containing Avonex followed by serum free Avonex</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Serum free Avonex followed by serum containing Avonex</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Serum containing Avonex</intervention_name>
    <description>60mcg IM dose of serum containing Avonex on Day 1, followed by 60mcg IM dose of serum free Avonex on Day 15</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <other_name>Avonex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Serum Free Avonex</intervention_name>
    <description>60mcg IM dose of serum free Avonex on Day 1, followed by 60mcg IM dose of serum containing Avonex on Day 15.</description>
    <arm_group_label>Sequence 2</arm_group_label>
    <other_name>Avonex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Volunteers

        Exclusion Criteria:

          -  History of severe allergic or anaphylactic reactions

          -  History of hypersensitivity to acetaminophen (paracetamol), ibuprofen, or codeine.

          -  Known allergy to dry natural rubber

          -  History of seizure disorder or unexplained blackouts

          -  History of any clinically significant (as determined by the Investigator) cardiac,
             endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary,
             neurologic, dermatologic, psychiatric, renal, and/or other major disease

        Other inclusion and exclusion criteria apply as per protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Biogen-Idec Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2009</study_first_submitted>
  <study_first_submitted_qc>June 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2009</study_first_posted>
  <last_update_submitted>June 3, 2009</last_update_submitted>
  <last_update_submitted_qc>June 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>Biogen Idec MD</name_title>
    <organization>Biogen Idec</organization>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Interferon beta-1a</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

